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Artery Study.2,3 Carotid endarterectomy can be compli-
cated by early or late recurrent carotid stenosis. Recurrences
within 2 years of the carotid endarterectomy are primarily
due to intimal hyperplasia, whereas later recurrences are fre-
quently due to atherosclerotic lesions.4 Smooth muscle cell
proliferation in the media after carotid endarterectomy con-
tributes to intimal hyperplasia with a resultant stenosis.5
These stenoses can lead to embolic or thrombotic neuro-
logic events.6 Subsets of patients can have minimal intimal
hyperplasia, whereas others may have an exaggerated inti-
mal hyperplasia response. Which category of stenosis devel-
opment a patient will fall into is unable to be determined at
this time.
The etiology of intimal hyperplasia remains incom-
pletely understood; however, several risk factors have been
associated with early recurrent stenosis. Young age, hyper-
tension, hyperlipidemia, female sex, small carotid artery,
primary closure, and smoking have all been associated with
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Objective: Hyperhomocysteinemia has been implicated as a causative factor in intimal hyperplasia development. The
addition of dietary folate in a hyperhomocysteinemia, carotid endarterectomy rat model is postulated to decrease
plasma homocysteine levels and, in turn, reduce post–carotid endarterectomy intimal hyperplasia.
Methods: Each rat was fed one of six diets: (1) lab chow with no folate (n = 7), (2) lab chow with 10 mg/kg folate
added (n = 3), (3) lab chow with 25 mg/kg folate added (n = 3), (4) a homocysteine diet with no folate (n = 7), (5)
a homocysteine diet with 10 mg/kg folate added (n = 5), or (6) homocysteine diet with 25 mg/kg folate added (n =
5). Each rat then underwent an open carotid endarterectomy. In 2 weeks, intimal hyperplasia in the carotid artery was
measured. Plasma homocysteine and folate levels were measured.
Results: Plasma folate levels rose with folate administration. Plasma homocysteine in the lab chow group was 5.4 ± 0.5
µmol/L and did not change with the addition of folate. In the homocysteine diet group, plasma homocysteine rose 10-
fold over the lab chow group (51.9 ± 6.5 vs 5.4 ± 0.5, µmol/L, P < .0001). In the group fed a homocysteine diet with
10 mg/kg folate added, a significant decrease in plasma homocysteine was observed (17.5 ± 8.5 vs 51.9 ± 6.5, µmol/L,
P = .0003). In the group fed a homocysteine diet with 25 mg/kg folate added, plasma homocysteine levels were fur-
ther reduced to levels seen in the lab chow group (12.6 ± 2.6 vs 5.4 ± 0.5, µmol/L, P = not significant). The rela-
tionship between plasma folate and homocysteine was inverse (R = 0.39, P = .0036). Luminal stenosis due to intimal
hyperplasia was minimal in lab chow groups and unaffected by folate. The homocysteine diet group demonstrated
post–carotid endarterectomy luminal stenosis due to intimal hyperplasia (60.9% ± 9.2%). In the group fed a homocys-
teine diet with 10 mg/kg folate added, intimal hyperplasia was reduced, compared with the homocysteine diet group
(32.6% ± 7.4% vs 60.9% ± 9.2%, P = .009). In the group fed a homocysteine diet with 25 mg/kg folate added, intimal
hyperplasia was reduced to lab chow group levels (10.8% ± 0.8% vs 4.8% ± 1.0%, P = not significant) and was reduced,
compared with the group fed a homocysteine diet with 10 mg/kg folate added.
Conclusion: The use of folate in this hyperhomocysteinemia carotid endarterectomy model and the resultant attenua-
tion of plasma homocysteine elevation and intimal hyperplasia development lend strong support to homocysteine being
an independent etiologic factor in post–carotid endarterectomy intimal hyperplasia. (J Vasc Surg 2001;34:474-81.)
increased risk.7,8 Interventions to prevent recurrence have
been largely unsuccessful.9 Our group has been interested
in an elevated plasma homocysteine level as a risk factor for
increased percentages of post–carotid endarterectomy inti-
mal hyperplasia and restenosis.
Homocysteine is a non–protein-forming amino acid
that is metabolized by remethylation to methionine or by
trans sulfuration to cysteine.10 Homocysteine elevation
may be the result of inherited disorders of enzyme activity
or from enzyme cofactor deficiencies of cobalamin, folate,
or pyridoxine with subsequent interruption of homocys-
teine metabolic pathways.11
Folate is a water-soluble vitamin synthesized by plants
and microorganisms and is not produced endogenously.
Folate supplies are therefore derived solely from foods
entering the body through intestinal absorption.12 Folate
functions in vivo by increasing the rate of homocysteine
remethylation to methionine, thereby reducing plasma
homocysteine levels.13 Folate supplementation has been
observed in various studies to lower plasma homocysteine
levels.14,15
Our laboratory has developed and established a rat
carotid endarterectomy model with arteriotomy, open
endarterectomy, and primary closure that produces signif-
icant intimal hyperplasia after endarterectomy.16 With the
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use of this endarterectomy model, plasma homocysteine
was elevated by the addition of dietary homocystine. Rats
with elevated plasma homocysteine developed markedly
increased intimal hyperplasia levels after endarterectomy
compared with rats given lab chow diets. The causal rela-
tionship between elevated homocysteine and increased
post–carotid endarterectomy intimal hyperplasia was not
investigated.
This study was designed to investigate the ability of
dietary folate supplementation to lower plasma homocys-
teine levels and the percentage of intimal hyperplasia in an
animal model with dietary-induced hyperhomocysteine-
mia. Our hypothesis was that dietary folate supplementa-
tion would lower plasma homocysteine levels and thus
decrease the degree of luminal stenosis caused by intimal
hyperplasia after carotid endarterectomy. If correct, this
would isolate homocysteine as an independent risk factor
for post–carotid endarterectomy intimal hyperplasia and
provide for an effective and uncomplicated treatment
option.
MATERIALS AND METHODS
Each Sprague-Dawley rat was randomly numbered
and assigned to one of six diet groups that were based on
either a lab chow diet or a homocysteine-supplemented
Control and homocysteine group diet components
Ingredients Control (g/kg) Homocysteine (g/kg)
L-arginine 12.7 12.7
L-histidine 3.4 3.4
L-lysine-hydrogen chloride 9.1 9.1
L-tyrosine 5.7 5.7
L-tryptophan 1.8 1.8
L-phenylalanine 7.3 7.3
L-methionine 1.7 0
L-cystine 3.7 3.7
L-threonine 4.6 4.6
L-leucine 10.5 10.5
L-isoleucine 6.1 6.1
L-valine 6.3 6.3
Glycine 6.2 6.2
L-proline 7.6 7.6
L-glutamic acid 28.9 28.9
L-alanine 5.1 5.1
L-aspartic acid 15.8 15.8
L-serine 7.2 7.2
Cornstarch 100 100
Dextrin 100 100
Cellulose 50 50
Sucrose 392.19 403.87
Sodium bicarbonate 4.3 4.3
Corn oil 50 50
Primex 100 100
Salt mix 35 35
Vitamin mix 10 (with folate*) 10 (without folate)
Choline bitartrate 14.48 0
Ferric citrate 0.33 0.33
DL-homocystine 0 4.5
Differences between diets are highlighted in bold print.
*Folate, 2.0 mg/10 mg vitamin mix.
diet. Folate was then added in some groups. The lab chow
diets consisted of a rat diet that was defined by choline-
and iron-supplemented L-amino acid (Diet #518754;
Dyets, Inc, Bethlehem, Pa). The homocysteine diets con-
sisted of a rat diet defined by choline-deficient and iron-
supplemented L-amino acid without folic acid or
methionine and with 4.5 g/kg DL-homocystine (Diet
#518790; Dyets; Table). The diets and number of rats in
each diet group were as follows: (1) lab chow with no
folate (n = 7), (2) lab chow with 10 mg/kg folate added
(n = 3), (3) lab chow with 25 mg/kg folate added (n = 3),
(4) homocysteine diet with no folate (n = 7), (5) homo-
cysteine diet with 10 mg/kg folate added (n = 5), or (6)
homocysteine diet with 25 mg/kg folate added (n = 5).
The rats were allowed water ad libitum and continued
their respective diets for 2 weeks before undergoing
carotid endarterectomy. After the carotid endarterectomy,
the rats continued their preoperative diet regimen for 2
weeks until they were humanely killed.
Elevation of plasma homocysteine can be accomplished
by adding homocysteine to the diet; however, this is expen-
sive. The same plasma level of homocysteine can be
achieved by adding the less expensive oxidized form of
homocysteine, DL-homocystine. Thus, our modified diet
with DL-homocystine has a lower cost, is well tolerated by
the rats (shown by weight gain), and has consistently ele-
vated plasma homocysteine levels of rats on this diet.16,17 In
the remainder of this report, diet groups with added homo-
cystine will be referred to as homocysteine diet groups.
The carotid endarterectomy was performed in an open
fashion with suture closure of the arteriotomy as previ-
ously described by our laboratory.16 Tissue harvesting was
performed after perfusion with saline and 10% formalin as
previously described.18
Homocysteine measurement. Plasma homocysteine
levels were measured with the Abbott IMx (Abbott
Laboratories, Abbott Park, Ill) automated homocysteine
assay. This is a fluorescence polarization immunoassay
based on the highly selective enzymatic conversion of
homocysteine to S-adenosyl-L-homocysteine (SAH) by
SAH hydrolase. Quantitative levels of SAH are deter-
mined in a competitive immunoassay with the use of a
monoclonal anti-SAH antibody.19
Folate measurement. Plasma folate levels were mea-
sured with a radioassay kit (Catalogue #KFSP2;
Diagnostic Products Corp, Los Angeles, Calif). A working
solution of folate labeled with iodine 125, a folate binder,
and 200 µL of plasma were combined. The resulting pre-
cipitant was separated from the supernatant and counted
with a gamma counter to determine plasma folate levels.
Morphometric analysis. After harvesting, the com-
mon carotid artery was paraffin blocked, sectioned, and
elastin stained with Verhoeff ’s and van Gieson’s stain.
Multiple sections were taken at intervals of 3 µm, each
continuing along the distance of the continuous 10-0
nylon suture arteriotomy closure to standardize the region
of sectioning. The elastin-stained slides were pho-
tographed with a Kodak DC 120 Zoom digital camera
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(Eastman Kodak Company, Rochester, NY). Images of the
carotid sections were then downloaded to a computer, and
the luminal areas of the carotids were analyzed with the
National Institutes of Health (Bethesda, Md) ImageJ
Software program, Version 0.99i. This software package
allowed us to delineate the inner area of intimal hyperpla-
sia and thus obtain an accurate measurement of the cross-
sectional area of the vessel lumen. The characteristic
pattern of intimal hyperplasia was used to identify the
demarcation between the outer limits of intimal hyperpla-
sia and the medial/adventitial layers. The difference
between the two areas (outer area of intimal hyperplasia
minus the actual lumen) was determined as the absolute
area of intimal hyperplasia. Because the arterial cross sec-
tion had individual variations of shape, the values were
expressed as a ratio of the absolute area of intimal hyper-
plasia to the outer limit of intimal hyperplasia and was
reported as a percent luminal stenosis. This ratio repre-
sents the proportion of the lumen area occupied by inti-
mal hyperplasia and allowed for comparison of the arterial
cross sections of varying size.20 Minimal variability was
seen between measurements with two blinded observers.
This study was approved by the Institutional Review
Board. All animal care complied with the Guide for the
Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council. Washington:
National Academy Press, 1996.
Statistical methods. Means ± SE are reported. One-
way analysis of variance with the Fisher exact pairwise
comparisons and regression analysis was used to evaluate
the difference among plasma homocysteine levels, folate
levels, and the percentage of luminal stenosis among the
dietary groups. This was performed with the Stat View
program (SAS Institute Inc, Cary, NC), version 5.0.
RESULTS
Folate supplementation of lab chow and homocysteine
diets produced a dose-dependent rise in plasma folate lev-
els. In the lab chow groups, the plasma folate rose 2.5
times in the diet supplemented with 25 mg/kg folate ver-
sus the diet with no folate supplementation (37.6 ± 12.9
ng/mL vs 14.6 ± 1.3 ng/mL, P < .05). In the homocys-
teine diet groups, plasma folate level rose 5.5 times in the
diet supplemented with 25 mg/kg folate versus the
homocysteine diet group without folate supplementation
(52.3 ± 13.5 ng/mL vs 10.0 ± 1.0 ng/mL, P = .0003).
Significant incremental increases were also observed with
the addition of 10 mg/kg folate to both the lab chow and
homocysteine diet groups. There was no significant differ-
ence in the serum folate level between the lab chow group
and homocysteine diet group that were not administered
folate (Fig 1).
The plasma homocysteine level in the lab chow group
was 5.4 ± 0.5 µmol/L and was not significantly different in
the lab chow groups with 10 mg/kg folate or 25 mg/kg
added (Fig 1). In the homocysteine diet group, plasma
homocysteine level rose almost 10-fold in comparison with
the lab chow group (51.9 ± 6.5 µmol/L vs 5.4 ± 0.5
µmol/L, P < .0001). In contrast to the lab chow group,
the addition of folate to the homocysteine diet groups pro-
duced significant decreases in the plasma homocysteine
level. In the homocysteine diet group with 10 mg/kg
folate added, the plasma homocysteine level was reduced
by two thirds (17.5 ± 8.5 µmol/L vs 51.9 ± 6.5 µmol/L,
P = .0003). In the homocysteine diet group with 25
mg/kg folate added, plasma homocysteine was further
reduced to levels observed in the lab chow group (12.6 ±
2.7 µmol/L vs 5.4 ± 0.5 µmol/L, P = not significant). A
significant inverse relationship was demonstrated between
plasma folate and homocysteine levels by means of loga-
rithmic regression analysis (R = 0.39, P = .0036; Fig 2).
Intimal hyperplasia producing luminal stenosis was
minimal in the lab chow groups and was not significantly
affected by folate supplementation (Fig 3). However, the
homocysteine diet group showed a significant amount of
luminal stenosis due to intimal hyperplasia (60.9% ± 9.2%)
when compared with the lab chow group (4.8% ± 1.0%, P
< .0001). In the homocysteine diet groups, the supple-
mentation of folate to the diets significantly reduced the
percentage of luminal stenosis due to intimal hyperplasia.
In the homocysteine diet group with 10 mg/kg folate
added, half of the amount of intimal hyperplasia was
observed when compared with the homocysteine diet
group (32.6% ± 7.4% vs 60.9% ± 9.2%, P = .009). In the
homocysteine diet group with 25 mg/kg folate added,
intimal hyperplasia was further reduced to one sixth the
level measured in the homocysteine diet group (10.8% ±
0.8%, P < .0001). The percentage of luminal stenosis in the
homocysteine diet group with 25 mg/kg folate added was
reduced to levels seen in the lab chow group (10.8% ± 0.8%
vs 4.8% ± 1.0%, P = not significant). The degree of luminal
stenosis created by intimal hyperplasia in the homocysteine
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diet group with 25 mg/kg folate added was significantly
decreased from the homocysteine diet group with 10
mg/kg folate added (P < .05). A stepwise decrease in inti-
mal hyperplasia was observed with increasing plasma folate
levels (Fig 1) and decreasing plasma homocysteine levels
(Fig 3). Representative photomicrographs of elastin-
stained carotid artery sections 2 weeks after carotid
endarterectomy are shown in Fig 4. Panels A, B, and C
show similar levels of intimal hyperplasia in the lab chow
group regardless of dietary folate supplementation. Panels
D, E, and F demonstrate decreasing luminal stenosis from
Fig 1. Plasma folate and homocysteine levels for each diet group.
Mean ± SE for plasma folate and homocysteine measured 2 weeks
after carotid endarterectomy. LC, Lab chow; H(e), homocysteine;
+ 10, 10 mg/kg folate added; + 25, 25 mg/kg folate added.
Asterisk indicates statistically significant difference between H(e)
and H(e) + 10; number sign indicates statistically significant dif-
ference between H(e) and H(e) + 25.
Fig 2. Regression analysis of plasma folate versus homocysteine.
Plasma folate and homocysteine measured 2 weeks after carotid
endarterectomy. Relationship is inversely correlated at P = .0036
with R = 0.39.
Fig 3. Intimal hyperplasia (% luminal stenosis) for each diet
group. Data are means + SE. Dietary homocysteine increased
post–carotid endarterectomy intimal hyperplasia. This increase is
attenuated with folate supplementation. Homocysteine with 25
mg/kg folate added resulted in intimal hyperplasia levels no dif-
ferent from lab chow groups. Asterisk equals statistically signifi-
cant difference between H(e) and H(e) + 10; number sign equals
statistically significant difference between H(e) and H(e) + 25.
intimal hyperplasia in the homocysteine diet group with
the addition of 0, 10, or 25 mg/kg of folate, respectively.
A significant, direct relationship between homocysteine
and intimal hyperplasia was demonstrated by means of loga-
rithmic regression analysis (R = 0.8, P < .0001; Fig 5). An
incremental increase in dietary folate administration pro-
duced an incremental decrease in plasma homocysteine,
which resulted in a proportional decrease in post–carotid
endarterectomy intimal hyperplasia (Figs 1 and 3).
DISCUSSION
Carotid endarterectomy is a proven treatment for
extracranial carotid artery stenosis.1,2 Post–carotid
endarterectomy intimal hyperplasia can complicate and
reduce the effectiveness of the endarterectomy procedure.
Although the recurrence rate for restenosis due to intimal
hyperplasia is relatively low, there is no current method of
detecting which patients will have postoperative intimal
hyperplasia.6 No known causative factor has been identi-
fied that could determine the extent of intimal hyperplasia
development. Previous work from our laboratory suggests
that homocysteine may be such a causative factor involved
in post–carotid endarterectomy intimal hyperplasia.16
Homocysteine is an attractive candidate for an etiologic
factor because of its ease of measurement and treatment.
In the previous work, plasma homocysteine was elevated
by dietary supplementation of homocysteine. Post–carotid
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endarterectomy intimal hyperplasia was reproducibly pres-
ent in control rats, and elevation of plasma homocysteine
resulted in significant levels of post–carotid endarterec-
tomy intimal hyperplasia. The findings of that study were
only descriptive in nature. No attempt was made to isolate
homocysteine separately as the causative factor in increased
post–carotid endarterectomy intimal hyperplasia, nor was
there an attempt at counteracting homocysteine’s potential
role in intimal hyperplasia development.
The current study used the same rat model and was
designed with two goals: (1) to identify and isolate elevated
plasma homocysteine as an independent risk factor for
increased post–carotid endarterectomy intimal hyperplasia
and (2) to identify an agent that could attenuate the poten-
tially increased intimal hyperplasia response in the environ-
ment of elevated plasma homocysteine. The use of dietary
folate in this rat carotid endarterectomy model was investi-
gated for its ability to accomplish both of these goals.
In this study, the addition of dietary folate resulted in
an increase in plasma folate in all groups receiving folate.
The addition of dietary folate was able to attenuate (10
mg/kg folate added) or completely eliminate (25 mg/kg
folate added) the hyperhomocysteinemia observed in rats
fed a homocysteine diet. The interaction between plasma
folate and homocysteine showed a significant inverse rela-
tionship. This finding confirmed that the modified homo-
cysteine diet used in this model was producing the elevated
Fig 4. Representative section of elastin-stained carotid artery from each diet group 2 weeks after carotid endarterectomy (10× magnifi-
cation). Arrows indicate extent of intimal hyperplasia. A, Lab chow = 6.4% intimal hyperplasia. B, Lab chow + 10 mg/kg folate = 1.6%
intimal hyperplasia. C, Lab chow + 25 mg/kg folate = 8.3% intimal hyperplasia. D, Homocysteine diet = 58.5% intimal hyperplasia. E,
Homocysteine diet + 10 mg/kg folate = 35.5% intimal hyperplasia. F, Homocysteine diet + 25 mg/kg folate = 11.8% intimal hyperpla-
sia. IH, Intimal hyperplasia.
plasma homocysteine level. Furthermore, the addition of
folate to that diet could increase the metabolism of homo-
cysteine in vivo and counteract the effect of dietary-induced
increases in plasma homocysteine. These findings are con-
sistent with the known mechanism of homocysteine metab-
olism. Folate supplementation thus provided the increase in
remethylation to decrease the plasma homocysteine levels.
The most significant finding of this study was the effect of
a reduced plasma homocysteine level on post–carotid
endarterectomy intimal hyperplasia. Folate supplementa-
tion reduced the percentage of post–carotid endarterec-
tomy intimal hyperplasia concomitantly with the reduction
observed in plasma homocysteine. The homocysteine diet
group with 10 mg/kg folate added demonstrated 50% of
the intimal hyperplasia observed in the homocysteine diet
group, whereas the homocysteine diet group with 25
mg/kg folate added demonstrated one sixth of the intimal
hyperplasia observed in the homocysteine diet group. In
previous work from our laboratory we have demonstrated a
threshold level for plasma homocysteine below which the
degree of intimal hyperplasia development is not different
from control rats.17 This level has been identified to be 15
µmol/L. In the homocysteine diet group with 10 mg/kg
folate added, plasma homocysteine was reduced to 17.5
µmol/L, and thus significant levels of intimal hyperplasia
above those of control rats were observed. However, with
the addition of 25 mg/kg of folate, plasma homocysteine
levels fell below 15 µmol/L, and no differences in intimal
hyperplasia were observed compared with control levels.
The addition of folate to lab chow diets had no effect on
intimal hyperplasia. Overall, these results support our
hypothesis that folate supplementation to rats with hyper-
homocysteinemia decreases plasma homocysteine levels and
produces a subsequent decrease in post–carotid endarterec-
tomy intimal hyperplasia. This implicates hyperhomocys-
teinemia as the sole causative factor for the exaggerated
intimal hyperplasia response seen in this model.
Hyperhomocysteinemia has been identified as an inde-
pendent risk factor for occlusive vascular disease by a
meta-analysis of 27 studies.21 In the Framingham Heart
study, the incidence of carotid artery disease was two times
higher in patients with elevated plasma homocysteine lev-
els.22 Although previous work with homocysteine and vas-
cular disease identifies its potential role in atherosclerosis,
the role of homocysteine in post–carotid endarterectomy
intimal hyperplasia may follow similar mechanisms.
Atherosclerosis involves smooth muscle cell proliferation
and migration after intimal damage and eventual plaque
formation.23 Intimal hyperplasia similarly involves a
process associated with smooth muscle cell activation,
migration, and proliferation.24 The role of homocysteine
in intimal hyperplasia may be significant. Both in vitro and
in vivo work shows that homocysteine can activate cells to
proliferate.25,26 The differentiating factor in regard to
patient populations that have an exaggerated intimal
hyperplasia response to carotid endarterectomy versus
normal amounts of intimal hyperplasia may be plasma
homocysteine levels. Given the potential importance of
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homocysteine in intimal hyperplasia, the role of folate also
takes on significance.
The homocysteine diet used in this study was specially
formulated with a deficiency of methionine and the
methyl donors choline and folate, with the addition of
homocysteine. With this diet, the homocysteine metabolic
pathway is unable to proceed with the breakdown of
homocysteine because of the lack of a methyl donor, lead-
ing to hyperhomocysteinemia. This diet ensures a consis-
tent and reproducible elevation of plasma homocysteine
levels. The ability to produce these elevated plasma homo-
cysteine levels with a simple dietary modification and with-
out apparent confounding side effects provides a useful
tool to study the effects of hyperhomocysteinemia in this
model and potential methods to reverse these effects. 
Homocysteine metabolism occurs through one of two
pathways: remethylation to methionine or transsulfuration
to cysteine. Transsulfuration occurs through the conversion
of homocysteine to cystathionine by the enzyme cystathion-
ine β-synthase. Alternatively, homocysteine may be remethy-
lated to methionine with either N-5-methyl-tetrahydrofolate
or betaine as the methyl donor. Remethylation is catalyzed
by the enzyme methylene tetrahydrofolate reductase, which
uses folate and vitamin B12 as cofactor or cosubstrate.27
The interrelationship between vitamin status and
plasma homocysteine levels was first reported by Kang et
al,28 who demonstrated an inverse relationship between
plasma homocysteine and folate levels. Many investigators
have confirmed this effect of folate supplementation low-
ering plasma homocysteine levels. Jacques et al14 showed
that fortification of enriched grain products with folic acid
significantly increased plasma folate levels and decreased
plasma homocysteine levels. Bunout et al15 have shown
that folate supplementation in patients with known coro-
nary artery disease significantly reduced plasma homocys-
Fig 5. Regression analysis of plasma homocysteine versus intimal
hyperplasia. Plasma homocysteine concentrations were measured
2 weeks after carotid endarterectomy. Degree of intimal hyper-
plasia is presented as percent luminal stenosis. Increasing levels of
plasma homocysteine and intimal hyperplasia are positively corre-
lated at R = 0.8 with P < .0001.
teine levels. The amount of folate supplementation varies
in these studies; however, many clinical investigations
examining the relationship of folate and homocysteine
have used a dosage of 5 mg/d.29-31
In vivo studies have shown that oral administration of
homocysteine-producing hyperhomocysteinemia leads to
significantly increased cellular proliferation rates.25,26
Homocysteine is a potent stimulant of DNA synthesis in
rat vascular smooth muscle cells as demonstrated by a four-
fold increase in bromodeoxyuridine-labeled nuclei. These
increases paralleled plasma homocysteine levels and con-
firmed the role of hyperhomocysteinemia in the induction
of DNA synthesis and cellular proliferation.26,32,33 After
endarterectomy, there are mitogenic influences that inter-
act to produce a “normal” amount of intimal hyperplasia.
In the setting of elevated plasma homocysteine levels, this
baseline intimal hyperplasia response may be synergistically
enhanced, thus producing an exaggerated intimal hyper-
plasia response. We have postulated that elevated plasma
homocysteine levels result in increased mitogenic stimula-
tion of smooth muscle cells producing an exaggerated 
intimal hyperplasia response in this post–carotid endarter-
ectomy model. The findings of this study support this the-
ory. Folate acting within the homocysteine metabolism
cycle lowers plasma homocysteine levels despite the addi-
tion of dietary homocysteine. Folate has no independent
activity in regard to intimal hyperplasia development. The
finding of decreased intimal hyperplasia with dietary
homocysteine and folate supplementation is evidence that
elevated homocysteine plays a causative role in the devel-
opment of the exaggerated post—carotid endarterectomy
intimal hyperplasia response.
The use of folate in this rat hyperhomocysteinemia
carotid endarterectomy model has isolated elevated homo-
cysteine as the causative factor in the exaggerated intimal
hyperplasia observed in this model. With the demonstra-
tion that elevated homocysteine can produce an intimal
hyperplasia response, the results from this animal model
can be used to speculate on the clinical significance. On the
basis of our results, the subset of patients at potential risk
for exaggerated post–carotid endarterectomy intimal
hyperplasia are individuals with hyperhomocysteinemia.
These patients could be identified preoperatively with a
blood analysis for homocysteine; if the homocysteine level
is elevated, the patients could begin folate therapy. The aim
of this therapy would be to lower plasma homocysteine
and, in turn, decrease the amount of post–carotid
endarterectomy intimal hyperplasia. The therapy would be
both easy to comply with and inexpensive. Ideally, the
identification and treatment of this at-risk group would
decrease the incidence of early, recurrent carotid stenosis
and the risk of neurologic sequelae.
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DISCUSSION
Dr Elliot L. Chaikof (Atlanta, Ga). Subclinical deficiencies of
vitamin B6, B12, or folate affect approximately 25% to 30% of the
adult population and are often associated with moderately ele-
vated homocysteine levels. Notably, the prevalence of elevated
homocysteine increases with age, in postmenopausal women, and
among patients with end-stage renal disease. A large body of
recent research has demonstrated that such elevations increase the
risk for cardiovascular disease, and associations with carotid steno-
sis, stroke, and peripheral vascular disease have all been described.
Smith, Moursi, and colleagues from the University of Arkansas
have developed a novel rat carotid endarterectomy model and are
to be congratulated on a well-conducted investigation that sup-
ports the notion that folate supplementation also inhibits homo-
cysteine-induced intimal hyperplasia. 
The Arkansas study, along with surveys of nutrient intake and
reports of the association of homocysteine levels with vascular dis-
ease, must lead us to conclude that increasing folate levels in intake
in the population at large would benefit homocysteine levels and
reduce vascular disease incidence. Indeed, NIH-sponsored random-
ized trials at the University of Oregon, Wake Forest, and
Georgetown University are underway to assess the role of folate sup-
plementation in the prevention of stroke, MI, and the progression of
PVD among a wide group of patients including those with ESRD.
No one can argue that it is always prudent to assess the effi-
cacy and safety of a new drug, but folic acid is a vitamin that peo-
ple have been taking for years and appears to be very safe. In fact,
since the identification that folate can reduce the incidence of
neural tube defects, bread, rolls, flour, pasta, rice, and cornmeal
have all been fortified with folate. The only caveat that folic acid
carries may be its potential to mask megaloblastic anemia, which
is caused by vitamin B12 deficiency. So I must ask the authors, if
the risk of folate is low and potential benefits significant, why
should we bother with further research? Perhaps they could elab-
orate on the objectives of future investigations. Should we not
advocate folate supplementation for all of our patients? What is
the current recommendation from the University of Arkansas? 
I would like to thank the society for the privilege of the floor.
Dr Todd Smith. Thank you Dr Chaikof for your complimen-
tary comments and interesting questions.
As you mentioned, the risks of folate supplementation are
very low, and if everybody can benefit from this, why should we
further study this? I think that was the initial question. I think like
most things, the role of the investigation is to actually prove to
ourselves and have objective evidence that this therapy is going to
do indeed what we planned on it doing. I think without knowing
specifically that this therapy is going to provide the expected
results, that is, potentially decrease intimal hyperplasia, we would
be remiss to recommend this to our patients as an absolute ther-
apy without that knowledge.
Second, at the University of Arkansas we do not currently
have any specific protocol either to measure homocysteine levels
to potentially identify patients at risk for this, nor do we have a
very stringent program to recommend or follow through with
folate supplementation. Both of these things are hopefully things
that can be implemented from these studies, as well as the clinical
studies showing reduction of risk with folate supplementation, so
that is something that we are actively pursuing at this time.
Dr Michael Sobel (Syracuse, NY). This was a very nice paper,
and the one question I had was, for your rats, how did the doses
of folate, the levels of folate, and the levels of homocysteine com-
pare with the human condition? For example, were your hyper-
homocysteinemic rats similar to the patients we might see with
homocysteinuria in terms of the elevations of homocysteine, and
likewise, did the folate supplementation of your rats compare with
the kind of folate supplementation we give to patients?
Dr Smith. The first question concerns the homocysteine level
of the diets. The homocysteine diet without folate supplimenta-
tion had the highest homocysteine level at 50 µmol/L. This level
is similar to that seen in patients with homocysteinuria, but higher
than the 15 to 20 µmol/L level seen in patients with moderate
hyperhomocysteinemia. In the groups that had the folate supple-
mentation in the homocysteine diet, these levels were reduced to
17 and 12, respectively. As far as the folate dosing, we picked
these doses to mimic that seen in the human, so that the 25
mg/kg of folate would closely represent that seen in the dose of
5 mg/d in the adult population.
Dr G. Patrick Clagett (Dallas, Tex). What do you think the
mechanism is underlying the elevated homocysteine and the inti-
mal hyperplasia? Is this a direct effect on smooth muscle cell
growth, or is it indirect through thrombogenic mechanisms? Is
there any corollary in human work with cell culture work demon-
strating that this effect is present?
Dr Smith. There is both in vitro and in vivo work that sup-
ports a direct mitogenic effect on smooth muscle cell proliferation
and an indirect effect through thrombogenic mechanisms. In our
current study, we did not specifically investigate which of these
mechanisms was responsible for the exaggerated intimal hyper-
plasia observed in this model. No arterial thrombosis was
observed, and we therefore do not feel a thrombogenic mecha-
nism was predominantly involved. We believe that a synergistic
effect exists between the arterial wall injury produced with the
endarterectomy and the hyperhomocysteinemia resulting in mito-
genic influences producing the intimal hyperplasia response that
we observed.
